Immunovia AB (publ) has been approved for trading of its shares on Nasdaq First North in Stockholm. The first trading day is December 1st, 2015. Immunovia is a Swedish research company that has developed a new method for using a blood test to diagnose pancreatic cancer. With Immunovia’s test, diagnosis can be made earlier which substantially enhances the possibilities to treat the cancer. A new share issue of SEK 60 million before issue costs have been carried out before introduction on First North.
Immunovia is a new exciting company in the life science sector on Nasdaq First North. With today’s approval, shares will be available for trading on December 1st. Prior to the introduction on First North, Immunovia carried out a new share issue that was oversubscribed five times. The share issue period ended November 16th, 2015 and provided the company with SEK 60 million before issue costs and about 1 100 new shareholders.
Immunovia has developed a new technology for cancer diagnostics. The capital injection from the share issue will finance the commercialization of the company’s blood test to diagnose pancreatic cancer. The blood-based test may be the world’s first of its kind for cancer diagnostics in this area. The funds will also be used to further develop similar tests for other cancers and for the autoimmune disease lupus (SLE).
The prospectus is available at Immunovia’s website, www.immunovia.com.
Trading InformationShort Name on Nasdaq First North: IMMNOVISIN-code: SE0006091997
Certified AdviserThe company’s Certified Advisor on Nasdaq First North is Wildeco Ekonomisk Information AB.
AdvisorVator Securities is the financial advisor and Baker & McKenzie legal advisor to the Company in connection with the listing on the Nasdaq First North, and the new share issue.
About ImmunoviaImmunovia AB was founded in 2007 by scientists from the Department of Immunotechnology at Lund University and CREATE Health – A Strategic Centre for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher a large amount of information in the blood and translate it into clinically useful tools to diagnose complex diseases such as cancer and to do this earlier and more accurately than previously possible. Immunovia’s core technology platform, IMMray™, is based on antibody microarray analysis. The company now performs clinical validation studies for commercialization of IMMray™ PanCan-d, which has the potential to become the first blood-based test for early diagnosis of cancer of the pancreas.
For more information please contact: Mats GrahnChief Executive Officer, CEO, ImmunoviaTel.: 46-70-5320230Email: email@example.com
Immunovia ABMedicon VillageScheelevägen 2SE-223 81 Lund